---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-25-009079"
form_type: "8-K"
ticker: "VBIO"
cik: "0001787740"
company_name: "Valion Bio, Inc."
filed_at: "2025-12-11T23:59:59+00:00"
generated_at: "2026-05-16T13:32:11.372363+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Tivic Health acquires Scorpius CDMO assets and closes $16.25M note and $12M preferred offerings

## Summary
- Acquired Scorpius CDMO assets for $16.25M cash via Article 9 sale through subsidiary Velocity Bioworks.
- Issued $16.25M senior secured convertible note to 3i, with 5% interest and 5-year maturity, to fund the acquisition.
- Sold 12,000 Series C preferred shares at $1,000 each for $12M in initial tranche; potential total up to $75M.
- Terminated $25M equity purchase agreement with Mast Hill Fund on December 9, 2025.
- Amended April 2025 purchase agreement with 3i to extend termination and lower floor price to $0.39.

## SEC filing metadata
- accession: 0001683168-25-009079
- form_type: 8-K
- ticker: VBIO
- cik: 0001787740
- company_name: Valion Bio, Inc.
- filed_at: 2025-12-11T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 5.03, 1.02, 2.01, 2.03, 3.02, 3.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787740/000168316825009079/0001683168-25-009079-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787740/000168316825009079/tivic_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-25-009079
- JSON: https://secwatch.observer/filing/0001683168-25-009079.json
- Plain text: https://secwatch.observer/filing/0001683168-25-009079.txt

## Source-grounded claims
- claim_id: a5878a4b150e9316011c6096fce0ba2ad3ca98e1
  claim: Valion Bio, Inc. incurred senior notes of $16,253,147.10 with 3i at 5.0% per annum maturing fifth anniversary of the issuance date.
  evidence_excerpt: a senior secured convertible note (the “Note”) in the principal amount of $16,253,147.10
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787740/000168316825009079/0001683168-25-009079-index.htm
- claim_id: 25889b33dbae88c2caf2d9bf133eeccc6a311f1a
  claim: Valion Bio, Inc.: Filed Certificate of Designation for Series C Non-Voting Convertible Preferred Stock, effective upon filing on December 9, 2025 (effective 2025-12-09).
  evidence_excerpt: On December 9, 2025, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of the Series C Non-Voting Convertible Preferred Stock (the “Certificate of Designation”) with the Secretary of State of the State of Delaware in connection with the Preferred Offering discussed above in Item 1.01. The Certificate of Designation became effective upon filing and designates 75,000 shares of the Company’s preferred stock as Series C Non-Voting Convertible Preferred Stock, par value $0.0001 per share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787740/000168316825009079/0001683168-25-009079-index.htm
- claim_id: f85426f01188b9526eb89c9190d1b5e2e46880d8
  claim: Valion Bio, Inc. completed an acquisition involving 3i, LP, as collateral agent for Scorpius Holdings, Inc. for $16,253,147.10 in cash (closed 2025-12-10).
  evidence_excerpt: provide similar services to other clients in the future. Pursuant to the APA, as consideration for the Acquired Assets, the Company (on behalf of VBI) paid the Collateral Agent $16,253,147.10 in cash at closing of the Acquisition. Consistent with customary practices in a sale under Article 9, the APA does not contain representations, warranties, covenants or
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787740/000168316825009079/0001683168-25-009079-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.